Insulin pumps – small devices that deliver insulin at regular intervals and on demand – are proving increasingly popular with patients with type 1 diabetes who find their glucose levels difficult to control with injections or who have other complications. They can offer significant benefits in terms of overall glucose control and patient's quality of life. In this article we review how insulin pumps have developed over the last 40 years, how modern pumps are used, which patients should be considered for their use and cost issues associated with these devices.
A new fixed dose combination of saxagliptin (Onglyza) and dapagliflozin (Forxiga) is now available for use in adults with type 2 diabetes.
Dr Matt Kearney, the new national clinical director for Cardiovascular Disease Prevention sets out his vision for cardiovascular disease (CVD) prevention in primary care.
We all know that diabetes prevalence is increasing. It is estimated that by 2025, 5 million people will have Type 2 diabetes in the UK (Diabetes UK). That potentially means more pressure on an already creaking healthcare system and more people at risk of developing debilitating complications from their diabetes. It doesn’t have to be that way!
Monitoring blood glucose levels is a central part of managing diabetes effectively. Inadequate monitoring can put a patient at risk of both short- and long-term complications. Maintaining near normal blood glucose levels helps to prevent immediate problems such as hypoglycaemia and hyperglycaemia and longer-term microvascular complications, including retinopathy, renal disease and neuropathy. There are many different ways in which diabetes can be monitored; this article focuses on self blood glucose monitoring.
Sitagliptin (trade name Januvia) is the first in a new class of drugs for diabetes – the dipeptidyl peptidase-4 (DPP-4) inhibitors. This new, oral hypoglycaemic agent has recently been approved for the treatment of type 2 diabetes. It is available on prescription and can be prescribed in primary care. Principal advantages include lack of weight gain and hypoglycaemia, which should make sitagliptin very popular with patients. This article looks at what a DPP-4 inhibitor is and how it works to lower blood glucose, as well as where this class of drug fits into current practice.
Healthcare professionals in England are being encouraged to refer people with diabetes who have severe insulin resistance and/or lipodystrophy to a specialist service based at Addenbrooke’s Hospital, Cambridge England that does not charge for referrals.